Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Summary
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmo...
Description
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmo...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source